Sionna Therapeutics, Inc.

NASDAQ:SION

Biotechnology

Healthcare
$2.97 +1.85%

+$0.68 today

Market cap
$134.35M
Beta
1.29
P/E (TTM)
-19.7
EPS (TTM)
-$1.90
52W Low $13.81High $48.45

Volume 0.52M

Average 0.39M

SION Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Sionna Therapeutics, Inc.NASDAQ: SION

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $154K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $453K.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly cost of revenue holds near $154K or moves back toward the trailing-twelve-month quarterly average of $113.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$154K+1.3% QoQ
Last fiscal yearDec 2025
$647K-3.1% YoY
LTMMar 2026
$453K+172.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-3.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
647K USD
Year-over-year change
-3.1%

Cost of Revenue vs competitors

How SION compares with its peers on the latest reported figures

  • SION's LTM Mar 2026 cost of revenue of $453K is the 10th highest of the 11 companies compared; the peer median is $5.99M.
  • Its year-over-year change of +172.9% is the highest of 6, against a peer median of -79.7%.
SION Competitors Peer median
Cost of Revenue for SION and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$83.4M ——31.4%
ABCLAbCellera Biologics Inc.LTM Sep 2026$80.53M —-24.3%118.7%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$57.97M +37.0%+33.1%18.4%
ARDXArdelyx, Inc.LTM Mar 2026$34.5M -39.4%+117.9%8.1%
JANXJanux Therapeutics, Inc.LTM Mar 2026$9.91M -79.7%+34.1%45.9%
BHVNBiohaven Ltd.LTM Jun 2026$2.07M ———
MAZEMaze Therapeutics, Inc.LTM Mar 2026$1.59M ——8.0%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$854K -99.5%—762.5%
IMNMImmunome, Inc.LTM Sep 2026$753K -98.5%——
SIONSionna Therapeutics, Inc.LTM Mar 2026$453K +172.9%——
VERAVera Therapeutics, Inc.LTM Jun 2026$0 ———
Peer median (excluding SION) $5.99M-79.7%+33.6%31.4%

Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue00668K647K
Gross Profit00(668K)(647K)
Gross Margin————
Research & Development34.61M40.63M57.29M60.26M
Selling, General & Admin6.77M9.71M13.27M28.72M
Operating Expenses41.37M50.33M69.89M88.34M
Depreciation & Amortization122K583K668K647K
EBITDA(40.12M)(46.68M)(61.02M)(74.62M)
EBITDA Margin————
Operating Income(41.37M)(50.33M)(70.56M)(88.98M)
Operating Margin————
Interest Income1.13M2.77M8.17M13.3M
Interest Expense0000
Other Income / Expenses1.13M3.07M8.87M13.71M
Income Before Tax(40.24M)(47.26M)(61.69M)(75.27M)
Pre-Tax Margin————
Income Tax Expense0000
Net Income(40.24M)(47.26M)(61.69M)(75.27M)
Net Margin————
EPS (Basic)(0.91)(1.07)(1.40)(1.88)
EPS (Diluted)(0.91)(1.07)(1.40)(1.88)
Weighted Avg Shares44.12M44.12M44.12M39.96M
Weighted Avg Shares (Diluted)44.12M44.12M44.12M39.96M

Sionna Therapeutics, Inc.

NASDAQ:SION

Intrinsic Alpha fair value

Locked

Current Price

$2.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.